{"doi":"10.1093/jnci/djad025","title":"Prophylactic human papillomavirus vaccination for prevention of oropharyngeal cancer in older men: is the juice worth the squeeze?","abstract":"Human papillomavirus (HPV) infection by 12-15 HPV genotypes (types) causes virtually all cervical cancer; most anal, penile, vulvar, and vaginal cancer; and a substantial proportion of head and neck squamous cell carcinoma (HNSCC), especially those of the oropharynx (1,2).HPV infection causes approximately 5% of cancers worldwide (3), with more than 60% due to HPV16 alone.Current prophylactic HPV vaccines are based on the selfassembly of recombinantly expressed L1 protein in cell lines into virus-like particles that resemble native viral capsids but without the viral genome, which is necessary for viral replication.There are currently 3 bivalent, 2 quadrivalent, and 1 nonavalent licensed prophylactic HPV vaccines (4).Bivalent vaccines Cervarix (GlaxoSmithKline; Wavre, Belgium), Cecolin (Xiamen Innovax Biotech Co Ltd; Xiamen, Fujian Province, China), and Walrinvax (Walvax Biotechnology Co; Kunming, Yunnan Province, China) target the 2 most carcinogenic types, HPV16 and HPV18.Two quadrivalent vaccines, Gardasil (Merck & Co, Kenilworth, NJ, USA) and Cervavac (Serum Institute of India (SII), Pune, India), target HPV16, HPV18, and HPV6 and HPV11, the later 2 types responsible for approximately 90% of genital warts (condyloma acuminata).The nonavalent vaccine Gardasil 9 (Merck) targets HPV6,11,16,18, 31, 33, 45, 52, and 58.Recent reports from Finland, Denmark, Sweden, and England provided real-world evidence that HPV vaccination statistically significantly reduces the incidence of cervical cancer (5-8); cervical cancer risk reduction decreased with increasing age at HPV vaccination.Although HPV vaccination prevents new HPV infec-","journal":"JNCI Journal of the National Cancer Institute","year":2023,"id":372212,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9614,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":285993,"name":"Philip E. Castle","orcid":"0000-0002-6408-5985","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T01:15:54.000926Z","pmid":"36782371","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}